Imipenem/Cilastatin Kabi (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem/Cilastatin Kabi is a broad‑spectrum carbapenem used for severe bacterial infections affecting various organ systems.

• Complicated intra‑abdominal infections: achieves rapid bacterial clearance and resolution of intra‑abdominal sepsis.
• Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary sterility.
• Hospital‑acquired pneumonia: provides effective coverage against multidrug‑resistant Gram‑negative and Gram‑positive organisms.
• Ventilator‑associated pneumonia: penetrates lung tissue to treat ventilator‑related infections.
• Septicemia: delivers systemic bactericidal activity to control bloodstream infections.

• Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell‑wall peptidoglycan synthesis, which leads to cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby maintaining therapeutic plasma concentrations.

Adverse reactions may occur with any antibacterial therapy. Monitoring for side effects is recommended.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: may be watery and self‑limiting.
• Injection site pain: localized discomfort at the IV site.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Rash: mild erythematous skin eruption.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction.
• Seizures: especially in patients with renal impairment or high plasma levels.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Neutropenia: marked reduction in neutrophil count.
• Hepatotoxicity: significant liver injury with jaundice.

Use of Imipenem/Cilastatin Kabi requires careful clinical assessment and monitoring.

• Renal function: adjust dosing in patients with impaired kidney function.
• History of seizures: avoid or use with caution in patients with prior seizure disorders.
• Allergies: confirm no known hypersensitivity to carbapenems or β‑lactams.
• Concomitant valproic acid: monitor for reduced antiepileptic effect.
• Pregnancy and lactation: weigh potential benefits against unknown risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin Kabi can interact with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Valproic acid: may reduce antiepileptic efficacy and increase seizure risk.
• Probenecid: can raise plasma concentrations, heightening toxicity.
• High‑dose aminoglycosides: additive nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Loop diuretics: monitor renal function and electrolytes.
• Warfarin: observe INR for potential anticoagulation changes.
• Rifampin: may decrease imipenem levels, reducing efficacy.